Dr. Acosta's genetic test MyPhenome can categorize individuals into types of weight gain, predicting response to semaglutide with 75% accuracy, aiding in personalized weight-loss treatment without trial and error.
Identifying those who will benefit from drugs like Wegovy can improve patient outcomes, reduce costs, and manage access better, potentially revolutionizing obesity treatment approaches.
[
add
]
[
|
|
...
]